Agenus (AGEN) vs TRex Bio (TRXB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
TRex Bio is the larger company by market cap ($385.1 million vs $335.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | AGEN | TRXB |
|---|---|---|
| Share price | $7.43 | $14.03 |
| Market cap | $335.55M | $385.06M |
| 1-day change | -3.13% | +0.21% |
| YTD return | +144.27% | — |
| 1-year return | +89.38% | — |
| 5-year return | -92.64% | — |
| P/E ratio (TTM) | 2.94 | — |
| EPS (TTM) | $2.53 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $114.20M | — |
| Revenue growth (YoY) | +10.37% | — |
| Net income (latest FY) | $-3.08M | — |
| Gross margin | 99.11% | — |
| Operating margin | -17.66% | — |
| Net margin | -2.70% | — |
| 52-week high | $10.31 | $15.50 |
| 52-week low | $2.71 | $13.50 |
| Distance from 52-week high | -27.93% | -9.48% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +254.37% | — |
| Average volume | 4.26M | 1.26M |
| Shares outstanding | 45.16M | 27.45M |
| Employees | 81 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About TRex Bio
TRXB stock →TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
AGEN vs TRXB FAQ
Which is bigger, Agenus or TRex Bio?
TRex Bio (TRXB) is larger, with a market capitalization of $385.06M compared with $335.55M for Agenus (AGEN).
Are Agenus and TRex Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.